Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo Qvantig
nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As subcutaneous monotherapy in the first-line treatment course for adults with unresectable or metastatic hepatocellular carcinoma following IV nivolumab plus ipilimumab combination therapy.
LAMPGEN ANALYSIS
Why it matters
This approval adds a subcutaneous continuation option after first-line IV dual immunotherapy.
What research teams should watch
Map the handoff after the combination phase and distinguish continuation from concurrent use with ipilimumab.
PRIMARY RECORDS